 Home > Medical News > Latest Medical News > The completion of the acquisition of two major multinational pharmaceutical companies is related to Novartis and Boehringer Ingelheim

The completion of the acquisition of two major multinational pharmaceutical companies is related to Novartis and Boehringer Ingelheim

 Last Update: 2021-10-11
 Source: Internet
 Author: User

Tags

effector cells

retrovirus gene therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Sunshine

On September 21, Novartis and Boehringer Ingelheim issued press releases one after another regarding the acquisition

Novartis acquires Arctos Medical to expand optogenetics product portfolio

This acquisition gives Novartis access to a preclinical optogenetics AAV gene therapy program and Arctos' proprietary technology

Arctos uses adeno-associated virus (AAV) gene therapy technology to deliver and express light genes to specific retinal cells, thereby replacing the function of photoreceptor cells

Arctos mainly develops potential treatments for inherited retinal dystrophy (IRD) and other diseases involving loss of photoreceptors (such as AMD)

Existing gene therapies aim to correct specific genes that cause vision loss

Boehringer Ingelheim acquires Abexxa Biologics to develop new cancer therapies

This acquisition will allow Boehringer Ingelheim to gain the expertise of Abexxa to target cancer-specific proteins located in cells and expand the range of potential cancer antigen targets

Abexxa focuses on the discovery and development of breakthrough antibody drugs, aiming to revolutionize cancer treatment through efficient targeting

Abexxa's innovative platform unlocks the ability to target intracellular antigens of cancer cells by identifying the presentation of MHC1 molecules on the cell surface

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.